T1	DISO 236 253	neurosintomáticos
T2	PROC 79 132	Ensayo clínico fase IV, abierto, randomizado y piloto
T3	CHEM 816 819	3TC
#1	AnnotatorNotes T3	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T4	DISO 168 182	neurotoxicidad
#2	AnnotatorNotes T4	C0235032; Neurotoxicity Syndromes; Injury or Poisoning
T5	CHEM 199 209	lamivudina
#3	AnnotatorNotes T5	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T6	CHEM 210 218	abacavir
#4	AnnotatorNotes T6	C0663655; abacavir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T7	CHEM 291 303	elvitegravir
#5	AnnotatorNotes T7	C2606637; elvitegravir; Organic Chemical · Pharmacologic Substance
T8	CHEM 304 314	cobicistat
#6	AnnotatorNotes T8	C3177235; cobicistat; Organic Chemical · Pharmacologic Substance
T9	CHEM 315 328	emtricitabina
#7	AnnotatorNotes T9	C0909839; emtricitabine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T10	CHEM 329 350	tenofovir alafenamida
T11	PROC 423 436	diagnosticado
#8	AnnotatorNotes T11	C0011900; Diagnosis; Diagnostic Procedure
T12	PROC 453 473	técnicas serológicas
T13	PROC 488 515	Tratamiento antirretroviral
#9	AnnotatorNotes T13	C1963724; Antiretroviral therapy; Therapeutic or Preventive Procedure
T14	PROC 542 557	Carga viral VIH
#10	AnnotatorNotes T14	C1168369; HIV viral load; Laboratory Procedure
T15	CHEM 812 815	DTG
T16	PROC 720 727	viremia
#11	AnnotatorNotes T16	C1261478; Viral load measurement; Laboratory Procedure
T17	DISO 852 860	síntomas
#12	AnnotatorNotes T17	C1457887; Symptoms; Sign or Symptom
T18	DISO 864 896	Síntomas de ansiedad o depresión
T19	DISO 952 969	Quejas cognitivas
T20	DISO 899 907	Insomnio
#13	AnnotatorNotes T20	C0917801; Sleeplessness; Sign or Symptom
T21	DISO 916 938	alteraciones del sueño
#14	AnnotatorNotes T21	C0037317; Sleep disturbances; Sign or Symptom
T22	DISO 941 948	Cefalea
#15	AnnotatorNotes T22	C0018681; Headache; Sign or Symptom
T23	DISO 1008 1039	Alteraciones del comportamiento
#16	AnnotatorNotes T23	C4540834; Alteration in behavior; Finding
T24	DISO 1041 1054	irritabilidad
#17	AnnotatorNotes T24	C0022107; Irritable Mood; Finding
T25	DISO 1070 1079	agitación
#18	AnnotatorNotes T25	C0085631; Agitation; Sign or Symptom
T26	DISO 1083 1088	Mareo
#19	AnnotatorNotes T26	C0012833; Dizziness; Sign or Symptom
T27	DISO 1257 1269	intolerancia
#20	AnnotatorNotes T27	C0277585; Intolerance to drug; Pathologic Function
T28	DISO 1248 1255	Alergia
#21	AnnotatorNotes T28	C1527304; Allergic Reaction; Pathologic Function
T29	DISO 1378 1405	infecciones activas del SNC
T30	ANAT 1402 1405	SNC
#22	AnnotatorNotes T30	C1269563; Entire central nervous system; Body System | C3714787; Central Nervous System; Body System
T31	DISO 1409 1417	Psicosis
#23	AnnotatorNotes T31	C0033975; Psychotic Disorders; Mental or Behavioral Dysfunction
T32	DISO 1426 1441	depresión mayor
#24	AnnotatorNotes T32	C1269683; Major Depressive Disorder; Mental or Behavioral Dysfunction
T33	DISO 1446 1465	síntomas psicóticos
T34	DISO 1518 1535	Consumo de drogas
T35	DISO 1468 1487	ideación autolítica
T36	DISO 1490 1498	Demencia
#25	AnnotatorNotes T36	C0497327; Dementia; Mental or Behavioral Dysfunction
T37	DISO 1501 1515	retraso mental
#26	AnnotatorNotes T37	C0025362; Mental Retardation; Mental or Behavioral Dysfunction | C3714756; Intellectual Disability; Mental or Behavioral Dysfunction
T38	CHEM 1360 1363	TAF
T39	PROC 1540 1551	diagnóstico
#27	AnnotatorNotes T39	C0011900; Diagnosis; Diagnostic Procedure
T40	DISO 1616 1628	Enfermedades
#28	AnnotatorNotes T40	C0012634; Disease; Disease or Syndrome
T41	PROC 1659 1673	procedimientos
#29	AnnotatorNotes T41	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure | C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T42	DISO 1688 1701	Claustrofobia
#30	AnnotatorNotes T42	C0008909; Claustrophobia; Mental or Behavioral Dysfunction
T43	ANAT 1730 1740	corporales
#31	AnnotatorNotes T43	C0460148; Human body structure; Anatomical Structure | C1318419; Entire human body; Anatomical Structure
T44	PROC 1802 1816	procedimientos
#32	AnnotatorNotes T44	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure | C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T45	PROC 1933 1954	método anticonceptivo
#33	AnnotatorNotes T45	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T46	CHEM 1351 1355	COBI
#34	AnnotatorNotes T46	C3177235; cobicistat; Organic Chemical · Pharmacologic Substance
T47	CHEM 186 198	dolutegravir
#35	AnnotatorNotes T47	C3253985; dolutegravir; Organic Chemical · Pharmacologic Substance
T48	DISO 232 235	VIH
#36	AnnotatorNotes T48	C0458074; Human immunodeficiency virus (HIV) status; Finding
T49	DISO 373 376	VIH
#37	AnnotatorNotes T49	C0458074; Human immunodeficiency virus (HIV) status; Finding
T50	DISO 440 443	VIH
#38	AnnotatorNotes T50	C0458074; Human immunodeficiency virus (HIV) status; Finding
T51	CHEM 500 515	antirretroviral
#39	AnnotatorNotes T51	C0599685; Anti-Retroviral Agents; Pharmacologic Substance
T52	PROC 627 641	consentimiento
#40	AnnotatorNotes T52	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T54	DISO 1056 1067	agresividad
#42	AnnotatorNotes T54	C0557883; Feeling aggressive; Finding
T55	PROC 1185 1203	carga viral de VIH
T56	DISO 1286 1311	mutaciones de resistencia
T57	DISO 1555 1560	abuso
#43	AnnotatorNotes T57	C0013146; Drug abuse; Mental or Behavioral Dysfunction 
T58	DISO 1563 1574	dependencia
#44	AnnotatorNotes T58	C1510472; Drug Dependence; Mental or Behavioral Dysfunction
T59	CHEM 1356 1359	FTC
#45	AnnotatorNotes T59	C0909839; emtricitabine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T60	CHEM 1347 1350	ELV
T61	CHEM 820 823	ABC
T62	CHEM 527 530	DTG
T63	CHEM 531 534	3TC
#46	AnnotatorNotes T63	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T64	CHEM 535 538	ABC
T65	Date 12 16	2016
T66	Spec_cue 158 167	potencial
T67	LIVB 222 231	pacientes
#47	AnnotatorNotes T67	C0030705; Patients; Patient or Disabled Group
T70	LIVB 405 413	Paciente
#48	AnnotatorNotes T70	C0030705; Patients; Patient or Disabled Group
T71	Age 414 422	>18 años
T73	Date 516 522	actual
T74	LIVB 554 557	VIH
#49	AnnotatorNotes T74	C0019682; HIV; Virus
T75	Duration 581 600	al menos 12 semanas
T76	Duration 696 715	al menos 12 semanas
T77	PHYS 959 969	cognitivas
#50	AnnotatorNotes T77	C0009240; Cognition; Mental Process
T78	PHYS 997 1004	memoria
#51	AnnotatorNotes T78	C0025260; Memory; Mental Process
T79	LIVB 1200 1203	VIH
#52	AnnotatorNotes T79	C0019682; HIV; Virus
T80	Duration 1221 1243	las últimas 12 semanas
T82	PHYS 1468 1476	ideación
#53	AnnotatorNotes T82	C0392348; ideation; Mental Process
T84	DEVI 1717 1729	dispositivos
#54	AnnotatorNotes T84	C1285539; Direct device; Medical Device
T85	LIVB 1832 1851	Mujeres embarazadas
#55	AnnotatorNotes T85	C0033011; Pregnant Women; Population Group
T86	LIVB 1854 1863	lactantes
#56	AnnotatorNotes T86	C4316174; Patients who are breastfeeding; Patient or Disabled Group
T87	LIVB 1874 1896	mujeres en edad fértil
#57	AnnotatorNotes T87	C4324275; Woman of childbearing potential; Population Group
T88	Age 1885 1896	edad fértil
T90	Neg_cue 1901 1903	no
T91	LIVB 548 553	viral
#58	AnnotatorNotes T91	C0042776; Virus; Virus
T92	PHYS 933 938	sueño
#59	AnnotatorNotes T92	C0037313; Sleep; Organism Function
T93	LIVB 1191 1196	viral
#60	AnnotatorNotes T93	C0042776; Virus; Virus
T94	PHYS 1509 1515	mental
#61	AnnotatorNotes T94	C0229992; Psyche structure; Mental Process
T68	PHYS 971 979	atención
#62	AnnotatorNotes T68	C0004268; Attention; Mental Process
T69	PHYS 981 994	concentración
#63	AnnotatorNotes T69	C0086045; Concentration (mental); Mental Process
T72	PHYS 1840 1851	embarazadas
#64	AnnotatorNotes T72	C0032961; Pregnancy; Organism Function
T81	CHEM 1529 1535	drogas
#65	AnnotatorNotes T81	C0086190; Illicit Drugs; Hazardous or Poisonous Substance
A1	Assertion T4 Speculated
A2	Population_data T87 Age
A3	Assertion T45 Negated
A4	Status T28 History_of
A5	Status T29 History_of
#66	AnnotatorNotes T2	C0282462; Phase 4 Clinical Trials; Research Activity + C1709323; Open Label Study; Research Activity + C0034656; Randomization; Research Activity + C0031928; Pilot Projects; Research Activity
#67	AnnotatorNotes T73	C0521116; Current (present time); Temporal Concept 
#68	AnnotatorNotes T62	C3253985; dolutegravir; Organic Chemical · Pharmacologic Substance
#69	AnnotatorNotes T15	C3253985; dolutegravir; Organic Chemical · Pharmacologic Substance
#70	AnnotatorNotes T64	C0663655; abacavir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
#71	AnnotatorNotes T61	C0663655; abacavir; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
#72	AnnotatorNotes T18	C0851406; Anxiety disorders and symptoms; Mental or Behavioral Dysfunction + C4716638; Signs and symptoms of depression; Finding 
#73	AnnotatorNotes T55	C1168369; HIV viral load; Laboratory Procedure
#74	AnnotatorNotes T34	C0242510; Drug usage; Mental or Behavioral Dysfunction
T89	Neg_cue 1757 1773	Inhabilidad para
T95	Observation 1774 1816	completar cualquiera de los procedimientos
A7	Assertion T95 Negated
R2	Negation Arg1:T89 Arg2:T95	
R1	Negation Arg1:T90 Arg2:T45	
R3	Speculation Arg1:T66 Arg2:T4	
T83	Spec_cue 1633 1639	puedan
T96	CONC 1640 1650	interferir
A6	Assertion T96 Speculated
#75	AnnotatorNotes T96	C0521102; Interferes with; Functional Concept
R4	Speculation Arg1:T83 Arg2:T96	
R6	Location_of Arg1:T43 Arg2:T84	
T97	Quantifier_or_Qualifier 1741 1754	magnetizables
R7	Experiences Arg1:T85 Arg2:T72	
R8	Has_Age Arg1:T87 Arg2:T88	
R10	Experiences Arg1:T87 Arg2:T45	
T98	Quantifier_or_Qualifier 1955 1963	adecuado
A8	Assertion T98 Negated
#76	AnnotatorNotes T98	C0205411; Adequate; Qualitative Concept
R9	Has_Quantifier_or_Qualifier Arg1:T45 Arg2:T98	
R11	Negation Arg1:T90 Arg2:T98	
R12	Combined_with Arg1:T47 Arg2:T5	
R13	Combined_with Arg1:T5 Arg2:T6	
R14	Before Arg1:T47 Arg2:T4	
R15	Experiences Arg1:T67 Arg2:T4	
R16	Experiences Arg1:T67 Arg2:T48	
R17	Experiences Arg1:T67 Arg2:T1	
R18	Overlap Arg1:T48 Arg2:T1	
R19	Combined_with Arg1:T7 Arg2:T8	
R20	Combined_with Arg1:T8 Arg2:T9	
R21	Combined_with Arg1:T9 Arg2:T10	
R22	Before Arg1:T47 Arg2:T7	
R23	Experiences Arg1:T67 Arg2:T7	
T99	Observation 259 273	reversibilidad
#77	AnnotatorNotes T99	C0679253; disease reversibility; Finding
R24	Experiences Arg1:T67 Arg2:T99	
R25	Before Arg1:T48 Arg2:T99	
R26	After Arg1:T99 Arg2:T7	
#78	AnnotatorNotes T10	C3713958; tenofovir alafenamide; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
R27	Has_Age Arg1:T70 Arg2:T71	
R28	Experiences Arg1:T70 Arg2:T50	
R29	Experiences Arg1:T70 Arg2:T12	
R30	Before Arg1:T12 Arg2:T11	
#79	AnnotatorNotes T12	C0036743; Serologic tests; Laboratory Procedure
R32	Overlap Arg1:T51 Arg2:T73	
R31	Combined_with Arg1:T62 Arg2:T63	
R33	Combined_with Arg1:T63 Arg2:T64	
R34	Used_for Arg1:T62 Arg2:T13	
R35	Used_for Arg1:T51 Arg2:T13	
T100	Result_or_Value 558 572	< 50 copias/mL
R36	Has_Result_or_Value Arg1:T14 Arg2:T100	
R37	Has_Duration_or_Interval Arg1:T14 Arg2:T75	
R38	Before Arg1:T14 Arg2:T52	
T101	Quantifier_or_Qualifier 662 681	dos determinaciones
R43	Has_Duration_or_Interval Arg1:T16 Arg2:T76	
T102	Result_or_Value 728 742	< 50 copias/mL
R44	Has_Result_or_Value Arg1:T16 Arg2:T102	
R45	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T101	
R46	Before Arg1:T16 Arg2:T52	
R47	Combined_with Arg1:T15 Arg2:T3	
R48	Combined_with Arg1:T3 Arg2:T61	
R49	Before Arg1:T15 Arg2:T17	
T103	Observation 769 782	empeoramiento
#80	AnnotatorNotes T103	C1457868; Worse; Finding
R50	Before Arg1:T15 Arg2:T103	
T104	Quantifier_or_Qualifier 1089 1110	de origen neurológico
R57	Has_Quantifier_or_Qualifier Arg1:T26 Arg2:T104	
T105	Quantifier_or_Qualifier 1113 1125	neuromediado
R58	Has_Quantifier_or_Qualifier Arg1:T26 Arg2:T105	
T106	Quantifier_or_Qualifier 1171 1184	al menos, una
R59	Has_Quantifier_or_Qualifier Arg1:T55 Arg2:T106	
T107	Result_or_Value 1204 1217	<50 copias/mL
R60	Has_Result_or_Value Arg1:T55 Arg2:T107	
R61	Overlap Arg1:T55 Arg2:T80	
R62	Causes Arg1:T60 Arg2:T28	
R63	Causes Arg1:T60 Arg2:T27	
R64	Combined_with Arg1:T60 Arg2:T46	
R65	Combined_with Arg1:T46 Arg2:T59	
R66	Combined_with Arg1:T59 Arg2:T38	
#81	AnnotatorNotes T60	C2606637; elvitegravir; Organic Chemical · Pharmacologic Substance
#82	AnnotatorNotes T38	C3713958; tenofovir alafenamide; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
R67	Location_of Arg1:T30 Arg2:T29	
T108	Quantifier_or_Qualifier 1418 1424	activa
#83	AnnotatorNotes T108	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R69	Has_Quantifier_or_Qualifier Arg1:T31 Arg2:T108	
R70	Overlap Arg1:T32 Arg2:T33	
#84	AnnotatorNotes T33	C0871189; Psychotic symptom; Sign or Symptom
R72	Causes Arg1:T81 Arg2:T57	
R73	Causes Arg1:T81 Arg2:T58	
T109	CONC 1608 1613	DSM-5
#85	AnnotatorNotes T109	C4236906; Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5); Intellectual Product
R74	Used_for Arg1:T109 Arg2:T39	
R75	Has_Quantifier_or_Qualifier Arg1:T84 Arg2:T97	
R40	Causes Arg1:T46 Arg2:T28	
R41	Causes Arg1:T46 Arg2:T27	
R42	Causes Arg1:T59 Arg2:T28	
R76	Causes Arg1:T59 Arg2:T27	
R77	Causes Arg1:T38 Arg2:T27	
R78	Causes Arg1:T38 Arg2:T28	
#41	AnnotatorNotes T29	C0007684; Central Nervous System Infection; Disease or Syndrome (?)
R79	Has_Duration_or_Interval Arg1:T16 Arg2:T75	
R39	Has_Duration_or_Interval Arg1:T14 Arg2:T76	
R5	Before Arg1:T17 Arg2:T103	
#86	AnnotatorNotes T56	C5704646; Drug resistance mutation; Cell or Molecular Dysfunction
#87	AnnotatorNotes T1	C0235031; Neurologic Symptoms; Sign or Symptom
A9	Experiencer T67 Patient
A10	Experiencer T70 Patient
A11	Experiencer T86 Patient
A12	Experiencer T85 Patient
A13	Experiencer T87 Patient
